Comments on: Monday Deal Review: August 31, 2009

By: Monday Biotech Deal Review: October 25, 2009 « The Cross-Border Biotech Blog

Mon, 26 Oct 2009 11:03:25 +0000

[...] Prism Medical Ltd. (TSXV: PM) put itself on the block, appointing Raymond James & Associates to look for “strategic alternatives” [following an undersubscribed placement in August]. [...]

By: Monday Biotech Deal Review: October 18, 2009 « The Cross-Border Biotech Blog

Mon, 19 Oct 2009 11:04:52 +0000

[...] at the time, Cardiome Pharma Corp. (NASDAQ: CRME) (TSX: COM) announced preliminary results of its modified Dutch Auction to purchase for cancellation USD$27.5 million of its common shares. More than $27.5 million of [...]

By: Next Steps for Cardiome: activated Protein C Program will Seek Other Funding « The Cross-Border Biotech Blog

Fri, 25 Sep 2009 20:12:03 +0000

[...] 25, 2009 · Leave a Comment When Cardiome (NASDAQ: CRME) (TSX: COM) announced its $27.5 million share buy-back program, the In Vivo Blog noted an earlier comment from its CEO, Doug Janzen, saying that Cardiome [...]

By: Monday Biotech Deal Review: September 14, 2009 « The Cross-Border Biotech Blog

Mon, 14 Sep 2009 11:02:41 +0000

[...] (NASDAQ: CRME) (TSX: COM) mailed the offer to purchase to its shareholders in connection with its previously-announced $27.5 million buy-back. Here are the docs on [...]